

Article

Synthesis and Biological Evaluation of New Bis-Indolinone Derivatives Endowed with Cytotoxic Activity

Rita Morigi ^{1,†}, Elena Catanzaro ^{2,†}, Alessandra Locatelli ^{1,*}, Cinzia Calcabrini ², Valentina Pellicioni ², Alberto Leoni ¹ and Carmela Fimognari ²

¹ Department of Pharmacy and Biotechnology, Alma Mater Studiorum—University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy; rita.morigi@unibo.it (R.M.); alberto.leoni@unibo.it (A.L.)

² Department for Life Quality Studies, Alma Mater Studiorum—University of Bologna, Corso d'Augusto 237, 47921 Rimini, Italy; elena.catanzaro2@unibo.it (E.C.); ccalcabrini@hotmail.com (C.C.); valentina.pellicioni2@unibo.it (V.P.); carmela.fimognari@unibo.it (C.F.)

* Correspondence: alessandra.locatelli@unibo.it; Tel.: +39-051-209-9712

† These authors contributed equally to this work.

Abstract: A series of new Knoevenagel adducts, bearing two indolinone systems, has been synthesized and evaluated on 60 human cancer cell lines according to protocols available at the National Cancer Institute (Bethesda, MD, USA). Some derivatives proved to be potent antiproliferative agents, showing GI₅₀ values in the submicromolar range. Compound **5b** emerged as the most active and was further studied in Jurkat cells in order to determine the effects on cell-cycle phases and the kind of cell death induced. Finally, oxidative stress and DNA damage induced by compound **5b** were also analyzed.

Keywords: programmed cell death; cell cycle; small molecules; indolinone systems; Knoevenagel reaction



Citation: Morigi, R.; Catanzaro, E.; Locatelli, A.; Calcabrini, C.; Pellicioni, V.; Leoni, A.; Fimognari, C. Synthesis and Biological Evaluation of New Bis-Indolinone Derivatives Endowed with Cytotoxic Activity. *Molecules* **2021**, *26*, 6277. <https://doi.org/10.3390/molecules26206277>

Academic Editor: Andrea Penoni

Received: 15 September 2021

Accepted: 11 October 2021

Published: 16 October 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction


Noncommunicable diseases (NCDs) are now responsible for the majority of global deaths, and cancer is expected to rank as the leading cause of death and the single most important barrier to increasing life expectancy in every country of the world in the 21st century [1]. Despite a variety of agents already used in anticancer therapy, drug resistance, toxicity, and side effects remain problems to be solved; hence, the development of new molecules still represents an attractive objective.

Programmed cell death (PCD) is a collective name that indicates any form of cellular death governed by an intracellular program, such as apoptosis, necroptosis, and ferroptosis. As opposed to accidental necrosis, PCDs allow cell death, maintaining cellular and tissue homeostasis and, in some instances, triggering a full-blown immune response [2–4]. For a long time, apoptosis has been considered the only PCD, but it has been clear from the last 60 years that cells can also commit suicide in a caspase-independent way. For instance, necroptosis is a form of regulated necrosis mediated by receptor-interacting protein kinase 1 (RIPK1), RIPK3, and pseudokinase mixed lineage kinase domain-like (MLKL). It has been discovered as an alternative regulated pathway triggered when apoptosis is impaired, and now, it is clear that it also represents a promising therapeutic target for chemotherapy [5]. Ferroptosis, on its side, is an iron-dependent PCD characterized by the accumulation of lipid peroxides. It was characterized only in 2012 but already represents an appealing alternative to necroptosis and apoptosis to overcome the unsatisfactory efficacy of current therapies [6,7]. Collectively, inducing one or more than one PCD at the same time accounts for an effective way to increase the chance of a successful therapeutic outcome.

The 2-indolinone scaffold holds a pivotal place as a pharmacophore for the development of anticancer agents, and, in addition, this scaffold has many pharmacological

activities [8]. In this field, our research group published many studies concerning new 2-indolinone derivatives as antiproliferative agents [9–12]. Some of our previous studies were devoted to the synthesis of bis-indole derivatives formed by two indole systems separated by a central moiety. Through this strategy, it was possible to identify several compounds endowed with a marked inhibition of cellular proliferation. Based on the most active antitumor agents previously described [13,14], this paper reports the synthesis, the studies on antitumor activity and mechanism of action of new derivatives with a framework bearing two indolinone nucleus or a central core pyrroloindoleione. The new derivatives were designed with the following rationale:

(1) the core, tetra-substituted benzene (4a–g) and di-substituted benzene (5b–f), has been maintained, and new substituents in the indolinone systems have been introduced (Scheme 1);




Compound	Starting Compound	R	R ₁	R ₂	R ₃
4a	1a	H	H	H	H
4b	1b	H	Br	H	H
4c	1c	H	Cl	H	H
4d	1d	CH ₃	Cl	H	H
4e	1e	H	OH	H	H
4f	1f	CH ₃	OH	H	H
4g	1g	H	H	CBR	
5b	1b	H	Br	H	H
5c	1c	H	Cl	H	H
5d	1d	CH ₃	Cl	H	H
5e	1e	H	OH	H	H
5f	1f	CH ₃	OH	H	H

CBR = condensed benzene ring.

Scheme 1. Synthesis of new derivatives 4a–g, 5b–f.

(2) the core has been substituted with 1,7-dimethyl-5,7-dihydropyrrolo [3,2-f]indole-2,6(1H,3H)-dione while maintaining the indole wings with different substituents (Scheme 2, compounds 8h–j).



Compound	Starting Compound	R	R ₁	R ₂
8h	6h	H	H	H
8i	6i	OH	H	H
8j	6j	H	CBR	

CBR = condensed benzene ring.

Scheme 2. Synthesis of new derivatives 8h–j.

In both cases, 2-indolinone is the scaffold of the new derivatives.

The antitumor activity of all the new compounds was evaluated according to the protocols available at the National Cancer Institute, Bethesda, MD (NCI).

In addition, we examined the efficacy of the most active compound to induce PCD on Jurkat cells.

2. Results and Discussion

2.1. Chemistry

The Knoevenagel reaction, employed in the synthesis of the new derivatives, involved the condensation of a carbonyl group with a methylene activated by a neighboring electron withdrawing group (Schemes 1 and 2). In the first case (Scheme 1, compounds 4a–g; 5b–f), the carbonyl groups were in the core, whereas the active methylene groups were in the indolinone wings. In the second case (Scheme 2, compounds 8h–j), this situation was inverted: the active methylene groups were in the core (pyrrolo [3,2-f]indole-2,6(1H,3H)-dione ring), whereas the carbonyl groups were in the indole wings.

Most of the new derivatives have been prepared with the same procedure described for the previously published compounds [13,14]: the appropriate indolinone 1 or 7 in methanol has been treated with the appropriate dicarbonyl 2,3 or 6 in the presence of piperidine (method 1). Since not all the designed compounds have been obtained under these reaction conditions, for the synthesis of compounds 4d–e, ethanol and HCl conc. have been used (method 2); for compound 5b, a mixture of acetic acid/hydrochloric acid has been employed (method 3); while for compounds 5c–d, toluene and p-toluenesulfonic acid have been used (method 4).

The structures of the final compounds were confirmed by means of IR, ¹H-NMR, ¹³C-NMR, and HRMS spectra. All of them were obtained as almost pure geometrical isomers, but their stability in DMSO-d₆ is not the same for all the compounds.

According to the ¹H-NMR spectra, all the compounds were obtained as *E* isomers, except 4e, 5b–e, and 8j, which also contain a small amount of the *Z* isomer. Furthermore, the long ¹³C-NMR acquisition times required, due to the presence of numerous quaternary carbons, led to complex mixtures as in the case of compound 5b (see Supporting Information). Therefore, for these compounds (4e, 5c–d, f) the ¹³C-NMR spectra were not recorded as the isomerization increases in DMSO-d₆ solution. The geometrical configuration was determined by performing NOE (Nuclear Overhauser Effect) experiments on derivatives 4b and 8h in order to evaluate whether the methine bridge and the proton at the 4 position of the indole (ind-4) are close in space (*Z* configuration) or not (*E* configuration). First of all,

we studied compound **4b**, and we noticed that the geometrical configuration of the two centers is the same, since the couple of NH groups and the other couples of indole protons (ind-4, ind-6, ind-7) give a single signal. The irradiation of ind-4 (7.58 ppm) produced NOE at the $-\text{C}(\text{CH}_3)_3$ group (singlet 1.33 ppm) and at the aromatic protons (singlet 7.77 ppm), whereas NOE was not observed at the $-\text{CH} =$ proton; the irradiation of the singlet at 1.33 ppm $-\text{C}(\text{CH}_3)_3$ produced NOE at 7.77 (aromatic protons) and at 7.58 ppm (ind-4). These data are in agreement with the *E* configuration.

The spectrum of derivative **8h** also shows that the geometrical configuration of the two centers is the same. For this compound, the irradiation of $-\text{CH} =$ protons at 7.37 ppm did not produce any effect on other protons. The lack of NOE demonstrates that even this compound belongs to the *E* configuration.

As far as compounds **5** are concerned, since the peaks of the ^1H -NMR spectra were too near for significant NOE experiments, we compared the common features of analog derivatives [14]. On this basis, we believe that these compounds also have the *E* configuration.

2.2. Biological Studies

2.2.1. Effects in Cultured Human Tumor Cell Lines

As a primary screening, the new compounds were submitted to the Developmental Therapeutics Program (DTP) at the National Cancer Institute (NCI) (<http://dtp.nci.nih.gov>) for evaluation of antitumor activity in the human cell line screen. In the preliminary test, compounds were tested at a single high concentration (10 μM) in the full NCI 60 cell panel (NCI 60 Cell One-Concentration Screen). This panel is organized into subpanels representing leukemia, melanoma, and cancers of the lung, colon, kidney, ovary, breast, prostate, and central nervous system. Only compounds with predetermined threshold inhibition criteria in a minimum number of cell lines progress to the full 5-concentration assay. These criteria were selected to efficiently capture compounds with antiproliferative activity based on careful analysis of historical DTP screening data. The results are expressed as the percentage of growth of treated cells relative to the control following a 48-h incubation. The one-concentration data is a mean graph of the percent growth of treated cells (unpublished results).

All but three of the compounds tested were subjected to the full 5-concentration assay. They were dissolved in DMSO and evaluated using five concentrations at ten-fold dilutions, the highest being 100 μM . Table 1 shows the results obtained (vincristine is reported for comparison purposes), which are expressed at three assay endpoints: the 50% growth inhibitory power (GI_{50}), the cytostatic effect ($\text{TGI} = \text{Total Growth Inhibition}$), and the cytotoxic effect (LC_{50}). For some derivatives, the 5-concentration test was repeated and no significant differences were found; in this case, the data reported in Table 1 are the mean values between the two experiments.

2.2.2. Structure—Activity Relationships

(a) Wings Modification

As far as the 4-*tert*-butyl-2,6-diformylphenol core is concerned, the shift of the chlorine from position 4 to 5 of the indolinone system increased the activity of compound **4c** (mean $\text{GI}_{50} = 1.15 \mu\text{M}$), which was more active than its parent compound described in the previous paper: (mean $\text{GI}_{50} = 2.7 \mu\text{M}$) [14], even in case of introduction of a methyl group in the indolinone NH (**4d**, mean $\text{GI}_{50} = 2.04 \mu\text{M}$), whereas the substitution of the chlorine with a bromine decreased the activity (**4b**, mean $\text{GI}_{50} = 2.88 \mu\text{M}$). The introduction of a hydroxy group in the same position led to a loss of activity (compound **4e** does not progress to the full five-concentrations assay), whereas the simultaneous introduction of a methyl group in the indolinone NH maintained the efficacy (**4f**, mean $\text{GI}_{50} = 3.09 \mu\text{M}$). A marked decrease in activity was observed both in the absence of substituents on the indolinone (**4a**, mean $\text{GI}_{50} = 5.13 \mu\text{M}$), as well as by introducing a condensed benzene ring (**4g**, mean $\text{GI}_{50} = 7.76 \mu\text{M}$). The most active derivatives (**4b–d**) were more effective toward the CNS tumor cell lines (GI_{50} 2.19; 1.29; 1.78 μM respectively).

Table 1. Nine subpanels at five concentrations: growth inhibition, cytostatic and cytotoxic activity (μM) of the selected compounds.

Comp ^a	Modes	Leukemia	NSCLC	Colon	CNS	Melanoma	Ovarian	Renal	Prostate	Breast	MG-MID ^b
4a	GI ₅₀	3.98	6.76	4.68	4.37	4.90	6.76	4.90	5.01	5.62	5.13
	TGI	21.38	20.89	16.60	17.38	16.60	20.42	18.62	16.60	18.20	18.62
	LC ₅₀	79.43	51.29	43.65	45.71	45.71	53.70	47.86	43.65	50.12	51.29
4b ^c	GI ₅₀	2.69	3.98	4.27	2.19	2.40	2.75	2.40	3.09	2.45	2.88
	TGI	11.48	13.80	13.80	7.94	7.08	11.48	11.48	13.18	7.76	10.47
	LC ₅₀	75.86	41.69	38.90	63.10	20.42	44.67	33.11	43.65	30.20	36.31
4c	GI ₅₀	1.86	2.57	2.45	1.29	1.66	1.82	2.24	1.95	1.82	1.95
	TGI	7.59	7.59	6.76	3.31	3.89	5.13	7.59	4.79	4.79	5.62
	LC ₅₀	51.29	20.89	21.88	8.32	9.33	20.89	22.39	15.49	17.38	18.20
4d	GI ₅₀	2.04	2.51	2.57	1.78	1.82	2.40	3.24	3.31	2.40	2.63
	TGI	12.59	8.13	8.71	8.32	4.27	8.91	10.23	13.18	12.02	8.51
	LC ₅₀	93.33	28.84	28.18	38.90	12.02	30.90	32.36	45.71	46.77	30.90
4f ^c	GI ₅₀	1.48	3.55	2.95	2.88	2.45	4.27	4.37	2.14	3.31	3.09
	TGI	8.91	10.72	8.13	9.77	6.92	15.49	12.88	9.12	15.14	10.47
	LC ₅₀	100.00	33.88	22.91	33.88	23.44	46.77	31.62	37.15	51.29	37.15
4g	GI ₅₀	3.31	7.94	11.22	6.76	7.41	7.94	12.30	6.76	5.75	7.76
	TGI	20.42	30.90	45.71	38.90	27.54	50.12	51.29	70.79	50.12	38.90
	LC ₅₀	97.72	79.43	79.43	83.18	79.43	79.43	85.11	100.00	95.50	83.18
5b ^c	GI ₅₀	0.51	1.62	0.63	1.10	0.72	1.35	0.98	1.10	0.74	0.91
	TGI	3.16	8.32	1.95	4.57	2.29	6.61	3.63	5.25	5.89	4.07
	LC ₅₀	61.66	43.65	7.59	19.50	8.91	31.62	16.22	25.70	23.99	21.38
5c	GI ₅₀	0.56	2.04	0.89	1.05	0.89	1.62	1.23	2.04	0.89	1.15
	TGI	5.50	7.59	2.19	3.98	2.19	7.08	3.72	12.88	4.68	4.27
	LC ₅₀	100.00	25.12	5.01	17.38	5.01	19.50	12.88	50.12	12.30	14.79
5d ^c	GI ₅₀	0.55	2.95	1.58	2.19	2.09	2.95	2.75	2.51	2.00	2.04
	TGI	6.61	29.51	5.01	12.88	6.76	13.18	22.91	45.71	12.02	12.88
	LC ₅₀	100.00	77.62	20.89	56.23	25.70	75.86	89.13	100.00	66.07	57.54
5e	GI ₅₀	2.95	3.98	2.63	2.19	2.14	4.79	6.17	2.69	2.57	3.24
	TGI	33.11	16.98	10.00	6.46	4.79	15.49	30.20	9.77	7.24	12.30
	LC ₅₀	100.00	47.86	44.67	28.18	15.85	54.95	69.18	56.23	41.69	45.71
5f	GI ₅₀	0.87	2.69	1.29	1.66	1.74	2.45	2.40	1.62	1.74	1.82
	TGI	11.22	7.08	2.88	3.72	3.55	7.24	4.90	3.39	5.13	5.01
	LC ₅₀	100.00	21.88	8.13	8.71	7.94	23.99	10.47	7.08	21.88	15.14
8h ^c	GI ₅₀	5.49	5.54	5.54	5.59	5.39	5.30	5.55	5.30	5.47	5.48
	TGI	4.46	4.26	4.44	4.37	4.29	4.12	4.28	4.16	4.21	4.29
	GI ₅₀	0.10	0.25	0.10	0.13	0.16	0.32	0.32	0.13	0.32	0.20
Vincristin- esulfate ^d	TGI	15.85	15.85	3.98	6.31	7.94	19.95	19.95	6.31	7.94	10.00

^a Highest conc. = 100 μM : only modes showing a value < 100 μM are reported. The compound exposure time was 48 h, ^b Mean graph midpoint, i.e., the mean concentration for all cell lines, ^c Mean of two separate experiments, ^d Highest conc. = 10^{-3}M .

When the core is a benzene ring, the shift of the chlorine from position 4 to 5 of the indolinone system led also to activity improvement of derivative **5c** (mean GI₅₀ = 1.15 μM), which proved to be more active than its parent compound described in the previous paper [14] (mean GI₅₀ = 2.4 μM), even in the case of introduction of a methyl group in the NH indolinone (**5d**, mean GI₅₀ = 2.04 μM). A particular mention is due to the substitution of the Cl with Br in position 5, which led to the most active compound of the whole series (**5b**, mean GI₅₀ = 0.91 μM). The introduction of a hydroxy group in the same position was detrimental, whereas the simultaneous introduction of a methyl group in the NH indolinone increased the activity (**5f**, mean GI₅₀ = 1.82 μM). All these derivatives were subjected to the full 5-concentration assay; **5b–d** and **f** were especially active toward leukemia cell lines (GI₅₀ 0.51; 0.56; 0.55; 0.87 μM , respectively).

Considering the potency and toxicity on leukemia cell lines, it is important to note that both series of compounds **4** and **5** showed a great difference between GI₅₀ and LC₅₀.

(b) Core modification

The substitution of the core with 1,7-dimethyl-5,7-dihydropyrrolo[3,2-f]indole-2,6(1H,3H)-dione (**8h–j**) led to a loss of activity; only one of the three compounds tested (**8h**) was subjected to the full 5-concentration assay.

2.2.3. Effect on Jurkat Cells Proliferation

The NCI 60 screening outlined **5b** as the most potent compound. For this reason, its antitumor and, in particular, its antileukemic potential have been investigated. Given the very favorable GI_{50} , the antiproliferative effect of **5b** has been firstly explored. On Jurkat cells, at all tested concentrations, **5b** promoted a significant decrease in the cells in the G2-M phase (27.7% at 2 μ M and 16.05 at 4 μ M versus 47.1% of untreated cells) (Figure 1). The decrease in the number of this cell's population was balanced by a slight increase in the percentage of cells in the G0–G1 (44.9% at 2 μ M and 44.3% at 4 μ M versus 37.3% of untreated cells) and by a substantial increase in cells in the subG0 phase (Figure 1), which represents cells characterized by fragmented DNA, i.e., dead cells. For example, untreated cells had less than 1% of subG0 cells compared to 13.5% and 28.7%, respectively, for **5b** 2 and 4 μ M (Figure 1). These interesting data prompt the following investigation about the cytotoxic potential of **5b**.




Figure 1. Histograms of cell-cycle distribution after Jurkat treatment with compound **5b** for 24 h. * $p < 0.05$; ** $p < 0.01$; **** $p < 0.0001$ versus untreated cells. Results are expressed as mean \pm SEM of at least three independent experiments. Two-way ANOVA followed by Dunnett's post-test was used to assess statistic and multiple comparisons.

2.2.4. Cytotoxic Effect on Jurkat Cells

5b induced a dose-dependent decrease in cell viability (Figure 2a). After 24 h, the IC_{50} was 3.20 μ M. At the same time point, we assessed the ability of **5b** to promote regulated cell death using the exposure of phosphatidylserine (PS) as a marker (Figure 2b,c). Indeed, during the early phases of the most characterized regulated cell deaths, dying cells experience a loss in plasma membrane symmetry and translocate intracellular PS on the outer membrane as a signal to be recognized and phagocytized by antigen-presenting cells [15,16]. However, Figure 2b shows that after 24 h, **5b**-treated cells are not in the early phases of any regulated cell death, since cells experience the cell membrane rupture, as shown by the double-positive population Annexin V⁺/7-amino-actinomycin D⁺ (AnnV⁺/7AAD⁺). AnnV is the cognate ligand of PS, and 7AAD has been used as a marker of cellular membrane integrity (Figure 2b,c). This means that the double positive cells are primary or secondary necrotic, i.e., in the late phases of cell death. To unravel whether the necrosis was primary or derived from an earlier cell death induction, PS exposure at an earlier time point was also investigated. After 1, 3, or 6 h, no significant PS exposure has been recorded (data not shown). PS exposure represents a universal and specific event that characterizes only regulated cell deaths, and it does not happen in necrotic cell death. Since at all time points, even just right after the treatment with the compound, cells do not experience PS exposure, but mainly membrane disruption (AnnV⁺/7AAD⁺), unregulated cell

death is, at least partially, involved in the **5b** mechanism of action. To further confirm this assumption, **5b** cytotoxicity has been tested alone or together with different inhibitors of the most characterized regulated cell deaths, namely necroptosis, apoptosis, or ferroptosis. Cell death was partially restored by the pan-caspase inhibitor Zvad-fmk (Zvad), and the effect was significant only at the highest tested concentration (Figure 2d). Thus, we can conclude that **5b** induces a mixed cell death, which seems only partially regulated, in the form of apoptosis.




Figure 2. Cytotoxic effect of **5b** on Jurkat cells. (a) Percentage of viable cells after 24 h treatment with **5b**; (b) Distribution of cells treated with **5b** for 24 h in the different stages of cell death: AnnV⁻/7AAD⁻ (viable); AnnV⁺/7AAD⁺ (late stage or primary necrotic); AnnV⁺/7AAD⁻ (early phase of regulated cell death); (c) representative dot plots of AnnV/7AAD assay of cells treated with **5b** for 24 h; (d) Percentage of cell death after treatment for 24 h with **5b** with or without inhibitors of apoptosis (Zvad), necroptosis (nec-1s), or ferroptosis (DFO). ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$ versus untreated cells. All results are expressed as mean \pm SEM of at least three independent experiments. Differences between treatments were assessed by one-way ANOVA followed by Dunnett's post-test (a,d), or two-way ANOVA followed by Dunnett's post-test (b).

2.2.5. Oxidative Stress and DNA Damage Analysis

Brominated compounds often induce oxidative stress and can generate DNA breaks [17]; thus, to further examine the mechanism of action of **5b**, the modulation of ROS levels and ability to induce DNA damage have been investigated. Starting at a lower concentration than that of IC₅₀, **5b** induced an increase in intracellular ROS levels already after 1 h (Figure 3a,b). At that time point, Jurkat cells treated with **5b** 1 μM hold around 3.03 times more ROS than untreated cells, while at the same time point, the effect of 4 μM **5b** is an increase of 5.92 compared to untreated cells (Figure 3a,b). Oxidative stress could represent a putative way through which **5b** induces the DNA damage that has been recorded. Indeed, at all tested concentrations, this compound promoted an increase in the phosphorylation of the histone H2A x (Ser139) (γH2Ax) (Figure 3c,d), which represents an early cellular response to double-strand breaks. The early DNA damage induced by **5b** could also explain why we showed that right after **5b** treatment, Jurkat cells lose membrane integrity. Indeed, early DNA damage, specifically DNA fragmentation, can lead to immediate late-stage apoptosis [18–20]. This type of cell death is typical of photodynamic therapy, where a photosensitizer, after specific irradiation, induces a burst of oxidative stress that generates DNA double-strand breaks that in turn kill the tumor cells [18,21]. For instance, brominated DAPI were shown to act in that way [18]. Thus, we hypothesize here that the high reactivity of **5b** could induce a similar effect without any irradiation.




Figure 3. (a) Relative expression of intracellular levels of ROS in Jurkat cells after **5b** exposure for 1, 3, and 6 h; (b) Representative histograms of flow cytometric analyses of cellular ROS contents of Jurkat cells after **5b** exposure for 1, 3 and 6 h; (c) Relative expression of γH2Ax in Jurkat cells after 6 h of **5b** exposure. Etoposide 10 μM was used as positive control; (d) Representative histogram of flow cytometric analyses of γH2Ax expression of Jurkat cells after **5b** exposure. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$ versus untreated cells. All results are expressed as mean \pm SEM of at least three independent experiments. Differences between treatments were assessed by two-way ANOVA followed by Dunnett's post-test (a), or one-way ANOVA followed by Dunnett's post-test (c).

3. Materials and Methods

3.1. Chemistry

The melting points are uncorrected. Elemental analyses were within $\pm 0.4\%$ of the theoretical values. Bakerflex plates (silica gel IB2-F) were used for TLC: the eluent was petroleum ether/acetone in various proportions. The IR spectra were recorded in nujol on a Nicolet Avatar 320 E.S.P.; ν_{\max} is expressed in cm^{-1} . $^1\text{H-NMR}$ and $^{13}\text{C-NMR}$ spectra were recorded in $(\text{CD}_3)_2\text{SO}$ on a Varian MR 400 MHz (ATB PFG probe, Crawley, United Kingdom); the chemical shift (referenced to solvent signal) is expressed in δ (ppm) and J in Hz; abbreviations: ar = aromatic, ind = indole. High-resolution mass spectrometry (HRMS) data were analyzed by flow injection, utilizing electrospray ionization (ESI) on a Waters Xevo G2-XS QTOF (Milford, MA, United States) instrument in the positive mode. Compounds were named relying on the naming algorithm developed by CambridgeSoft Corporation (Perkin Elmer, Milan, Italy) and used in Chem-BioDraw Ultra 14.0 (Perkin Elmer, Milan, Italy). $^1\text{H-NMR}$, $^{13}\text{C-NMR}$, and HRMS spectra are reported as Supplementary Materials. All solvents and reagents, unless otherwise stated, were supplied by Aldrich Chemical Co. Ltd. (Milan, Italy) and were used without further purification.

Indolin-2-one **1a**, 5-bromoindolin-2-one **1b** [22], 5-chloroindolin-2-one **1c**, 5-chloro-1-methylindolin-2-one **1d** [23], 5-hydroxyindolin-2-one **1e** [24], 5-hydroxy-1-methylindolin-2-one **1f** [25], 1,3-dihydro-2H-benzo[g]indol-2-one **1g** [26], 4-*tert*-butyl-2,6-diformylphenol **2**, benzene-1,3-dicarbaldehyde (isophthalaldehyde) **3**, 2-chloro-1H-indole-3-carbaldehyde **6h** [27], 2-chloro-5-hydroxy-1H-indole-3-carbaldehyde **6i** [28], 2-chloro-1H-benzo[g]indole-3-carbaldehyde **6j** [9], and 1,7-dimethyl-5,7-dihydropyrrolo[3,2-f]indole-2,6(1H,3H)-dione **7** [29] are commercially available or have been prepared as described in the literature.

3.2. Synthesis of Compounds **4a–g**, **5b–f**, **8h–j**

Four different methods were employed.

3.2.1. Method 1 (Compounds **4a–c**, **f–g**, **5e–f**, **8h–j**)

The proper compound **1** (10 mmol) was dissolved in methanol (100 mL) and treated with the appropriate aldehyde **2** or **3** (5 mmol) and piperidine (2 mL). The reaction mixture was refluxed for 3–8 h (according to a TLC test), cooled and, if necessary, concentrated at reduced pressure or treated with water (100 mL). The yellow to orange precipitate thus formed was collected by filtration. The compounds were subjected to biological tests after crystallization from ethanol.

Since compounds **8** have an indolinone central core, the same procedure was used for their synthesis, but the stoichiometric ratios have been inverted: 5 mmol of the indolinone **7** and 10 mmol of the appropriate aldehyde **6**.

3,3'-((5-(tert-butyl)-2-hydroxy-1,3-phenylene)bis(methaneylylidene))bis(indolin-2-one), **4a**, Yield 15%; IR (Nujol) ν_{\max} : 1705, 1608, 1224, 733 cm^{-1} ; $^1\text{H-NMR}$ (DMSO- d_6): δ 1.26 (9H, s, $3 \times \text{CH}_3$), 6.82 (2H, t, ind, $J = 7.6$), 6.86 (2H, d, ind, $J = 7.6$), 7.19 (2H, t, ind, $J = 7.6$), 7.45 (2H, d, ind, $J = 7.6$), 7.71 (2H, s, ar), 7.73 (2H, s, CH), 9.88 (1H, broad, OH), 10.56 (2H, s, NH); $^{13}\text{C-NMR}$ (DMSO- d_6): 31.10, 34.28, 110.14, 120.86, 121.14, 122.41, 123.10, 127.51, 128.58, 129.99, 132.30, 142.87, 168.65; HRMS: m/z calculated for $\text{C}_{28}\text{H}_{24}\text{N}_2\text{NaO}_3$ [$M + \text{Na}$] $^+$: 459.16846. Found: 459.16795; Anal. Calcd. for $\text{C}_{28}\text{H}_{24}\text{N}_2\text{O}_3$ (MW 436,51): C, 77.04; H, 5.54; N, 6.42; Found C, 77.05; H, 5.56; N, 6.39.

3,3'-((5-(tert-butyl)-2-hydroxy-1,3-phenylene)bis(methaneylylidene))bis(5-bromoindolin-2-one), **4b**, Yield 45%; IR (Nujol) ν_{\max} : 1708, 1607, 1260, 1224 cm^{-1} ; $^1\text{H-NMR}$ (DMSO- d_6): δ 1.33 (9H, s, $3 \times \text{CH}_3$), 6.85 (2H, d, ind-7, $J = 8.2$), 7.40 (2H, dd, ind-6, $J = 8.2$, $J = 2.0$), 7.58 (2H, d, ind-4, $J = 2.0$), 7.77 (2H, s, ar), 7.82 (2H, s, CH), 10.08 (1H, broad, OH), 10.77 (2H, s, NH); $^{13}\text{C-NMR}$ (DMSO- d_6): δ 31.48, 34.76, 112.41, 112.99, 123.29, 123.71, 125.05, 127.07, 129.45, 132.57, 134.59, 142.35, 168.57; HRMS: m/z calculated for $\text{C}_{28}\text{H}_{23}\text{Br}_2\text{N}_2\text{O}_3$ [$M + \text{H}$] $^+$: 593.00754. Found: 595.00656; Anal. Calcd for $\text{C}_{28}\text{H}_{22}\text{Br}_2\text{N}_2\text{O}_3$ (MW: 594,30): C, 56.59; H, 3.73; N, 4.71; Found C, 56.57; H, 3.75; N, 4.74.

3,3'-((5-(tert-butyl)-2-hydroxy-1,3-phenylene)bis(methaneylylidene))bis(5-chloroindolin-2-one), **4c**, Yield 60%; IR (Nujol) ν_{\max} : 1707, 1607, 1312, 1260 cm^{-1} ; $^1\text{H-NMR}$ (DMSO- d_6): δ 1.32 (9H, s, 3 \times CH₃), 6.90 (2H, d, ind-7, J = 8.0), 7.28 (2H, dd, ind-6, J = 8.0, J = 2.0), 7.44 (2H, d, ind-4, J = 2.0), 7.77 (2H, s, ar), 7.83 (2H, s, CH), 10.08 (1H, broad, OH), 10.74 (2H, s, NH); $^{13}\text{C-NMR}$ (DMSO- d_6): δ 31.00, 34.33, 111.46, 121.93, 122.80, 124.83, 129.15, 134.20, 141.56, 168.29; HRMS: m/z calculated for C₂₈H₂₂Cl₂N₂O₃ [M + H]⁺: 505.10857. Found: 505.10852; Anal. Calcd for C₂₈H₂₂Cl₂N₂O₃ (MW: 505,40): C, 66.54; H, 4.39; N, 5.54; Found C, 66.57; H, 4.36; N, 5.52.

3,3'-((5-(tert-butyl)-2-hydroxy-1,3-phenylene)bis(methaneylylidene))bis(5-hydroxy-1-methylindolin-2-one), **4f**, Yield 15%; IR (Nujol) ν_{\max} : 1677, 1650, 1595, 1213 cm^{-1} ; $^1\text{H-NMR}$ (DMSO- d_6): δ 1.30 (9H, s, 3 \times CH₃), 3.17 (6H, s, CH₃), 6.75 (2H, dd, ind-6, J = 8.0, J = 2.4), 6.85 (2H, d, ind-7, J = 8.0), 7.04 (2H, d, ind-4, J = 2.4), 7.75 (2H, s, ar), 7.76 (2H, s, CH), 9.02 (2H, s, OH), 9.92 (1H, s, OH); $^{13}\text{C-NMR}$ (DMSO- d_6): δ 25.95, 30.98, 34.31, 108.75, 110.37, 116.16, 121.21, 122.43, 122.95, 127.24, 128.68, 132.52, 136.56, 152.47, 167.06; HRMS: m/z calculated for C₃₀H₂₉N₂O₅ [M + H]⁺: 497.20765. Found: 497.20733; Anal. Calcd for C₃₀H₂₈N₂O₅ (MW: 496,56): C, 72.56; H, 5.68; N, 5.64; Found C, 72.58; H, 5.65; N, 5.63.

3,3'-((5-(tert-butyl)-2-hydroxy-1,3-phenylene)bis(methaneylylidene))bis(1,3-dihydro-2H-benzoglindol-2-one), **4g**, Yield 10%; IR (Nujol) ν_{\max} : 1701, 1614, 1311, 1265 cm^{-1} ; $^1\text{H-NMR}$ (DMSO- d_6): δ 1.33 (9H, s, 3 \times CH₃), 7.44 (2H, d, ind, J = 8.4), 7.53 (4H, m, ind), 7.64 (2H, d, ind, J = 8.4), 7.85 (2H, s, ar), 7.86 (2H, s, CH), 7.88 (2H, m, ind), 8.15 (2H, m, ind), 10.04 (1H, broad, OH), 10.41 (2H, s, NH); $^{13}\text{C-NMR}$ (DMSO- d_6): δ 30.52, 34.25, 114.89, 119.41, 120.31, 122.61, 123.26, 127.01, 128.18, 128.45, 128.89, 132.07, 133.91, 139.99, 169.73; HRMS: m/z calculated for C₃₆H₂₈N₂NaO₃ [M + Na]⁺: 559.19976. Found: 559.19979; Anal. Calcd for C₃₆H₂₈N₂O₃ (MW: 536,63): C, 80.58; H, 5.26; N, 5.22; Found C, 80.59; H, 5.28; N, 5.19.

3,3'-(1,3-phenylenebis(methaneylylidene))bis(5-hydroxyindolin-2-one), **5e**, Yield 20%; IR (Nujol) ν_{\max} : 1701, 1614, 1311, 1265 cm^{-1} ; $^1\text{H-NMR}$ (DMSO- d_6): δ 6.67 (4H, m, ind-6+ind-7), 7.02 (2H, d, ind-4, J = 1.6), 7.62 (2H, s, CH), 7.68 (1H, t, ar, J = 8), 7.79 (1H, d, ar, J = 8), 7.88 (1H, s, ar), 9.04 (2H, s, OH), 10.31 (2H, s, NH); $^{13}\text{C-NMR}$ (DMSO- d_6): δ 109.97, 110.63, 117.01, 121.40, 129.02, 129.17, 129.89, 134.61, 13.07, 135.46, 151.87, 168.57; HRMS: m/z calculated for C₂₄H₁₇N₂O₄ [M + H]⁺: 397.11883. Found: 397.11863; Anal. Calcd for C₂₄H₁₆N₂O₄ (MW: 396,40): C, 72.72; H, 4.07; N, 7.07; Found C, 72.70; H, 4.05; N, 7.09.

3,3'-(1,3-phenylenebis(methaneylylidene))bis(5-hydroxy-1-methylindolin-2-one), **5f**, Yield 30%; IR (Nujol) ν_{\max} : 1678, 1598, 1217, 1118 cm^{-1} ; $^1\text{H-NMR}$ (DMSO- d_6): δ 3.15 (6H, s, CH₃), 6.74 (2H, dd, ind-6, J = 8.0, J = 2.0), 6.85 (2H, d, ind-7, J = 8.0), 7.07 (2H, d, ind-4, J = 2.0), 7.69 (1H, t, ar, J = 7.4), 7.72 (2H, s, CH), 7.81 (2H, d, ar, J = 7.4), 7.91 (1H, s, ar), 9.15 (2H, s, OH); HRMS: m/z calculated for C₂₆H₂₁N₂O₄ [M + H]⁺: 425.15013. Found: 425.15010; Anal. Calcd for C₂₆H₂₀N₂O₄ (MW: 424,46): C, 73.57; H, 4.75; N, 6.60; Found C, 73.55; H, 4.76; N, 6.61

3,5-bis((2-chloro-1H-indol-3-yl)methylene)-1,7-dimethyl-5,7-dihydropyrrolo[3,2-f]indole-2,6-(1H,3H)-dione, **8h**, Yield 20%; IR (Nujol) ν_{\max} : 1681, 1604, 1271, 1127 cm^{-1} ; $^1\text{H-NMR}$ (DMSO- d_6): δ 3.30 (6H, s, CH₃), 6.38 (1H, s, ar), 6.45 (2H, d, ind, J = 7.6), 6.59 (2H, t, ind, J = 7.6), 6.87 (2H, t, ind, J = 7.6), 6.91 (1H, s, ar), 7.15 (2H, d, ind, J = 7.6), 7.37 (2H, s, CH), 12.16 (2H, s, NH); $^{13}\text{C-NMR}$ (DMSO- d_6): δ 26.26, 90.52, 106.53, 11.50, 113.74, 119.18, 120.10, 121.50, 122.88, 123.12, 123.98, 126.18, 134.23, 144.53, 168.09, HRMS: m/z calculated for C₃₀H₂₁Cl₂N₄O₂ [M + H]⁺: 539.10416. Found: 539.10237; Anal. Calcd for C₃₀H₂₀Cl₂N₄O₂ (MW: 539,42): C, 66.80; H, 3.74; N, 10.39; Found C, 66.83; H, 3.71; N, 10.38.

3,5-bis((2-chloro-5-hydroxy-1H-indol-3-yl)methylene)-1,7-dimethyl-5,7-dihydropyrrolo[3,2-f]indole-2,6-(1H,3H)-dione, **8i**, Yield 15%; IR (Nujol) ν_{\max} : 1678, 1609, 1273, 1134, 1108 cm^{-1} ; $^1\text{H-NMR}$ (DMSO- d_6): δ 3.32 (6H, s, CH₃), 5.82 (2H, d, ind-4, J = 1.9), 6.40 (2H, dd, ind-6, J = 8.8, J = 1.9), 6.47 (1H, s, ar), 6.89 (1H, s, ar), 6.93 (2H, d, ind-7, J = 8.8), 7.38 (2H, s, CH), 8.42 (2H, s, OH), 11.87 (2H, s, NH); $^{13}\text{C-NMR}$ (DMSO- d_6): δ 26.25, 90.20, 104.50, 106.09, 11.39, 112.05, 114.09, 123.17, 123.66, 124.20, 125.85, 128.39, 144.02, 151.41, 168.28; HRMS:

m/z calculated for $C_{30}H_{21}Cl_2N_4O_4$ $[M + H]^+$: 571.09399. Found: 571.09044; Anal. Calcd for $C_{30}H_{20}Cl_2N_4O_4$ (MW: 571,41): C, 63.06; H, 3.53; N, 9.81; Found C, 63.08; H, 3.50; N, 9.82.

*3,5-bis((2-chloro-1H-benzo[*g*]indol-3-yl)methylene)-1,7-dimethyl-5,7-dihydropyrrolo[3,2-*fl*indole-2,6(1H,3H)-dione*, **8j**, Yield 15%; IR (Nujol) ν_{\max} : 1659, 1603, 1269, 1125 cm^{-1} ; 1H -NMR (DMSO- d_6): δ 3.33 (6H, s, CH_3), 6.69 (2H, d, ind, $J = 8$), 6.89 (1H, s, ar), 6.94 (1H, s, ar), 7.03 (2H, d, ind, $J = 8$), 7.35 (2H, t, ind, $J = 8$), 7.43 (2H, s, CH), 7.47 (2H, t, ind, $J = 8$), 7.61 (2H, d, ind, $J = 8$), 7.78 (2H, d, ind, $J = 8$), 12.03 (2H, s, NH); ^{13}C -NMR (DMSO- d_6): δ 26.33, 108.18, 113.72, 119.44, 119.60, 119.96, 120.34, 120.82, 123.01, 123.39, 123.69, 124.12, 125.48, 127.60, 129.18, 129.21, 144.76, 168.21; HRMS: m/z calculated for $C_{38}H_{25}Cl_2N_4O_2$ $[M + H]^+$: 639.13546. Found: 639.13362; Anal. Calcd for $C_{38}H_{24}Cl_2N_4O_2$ (MW: 639,54): C, 71.37; H, 3.78; N, 8.76; Found C, 71.33; H, 3.80; N, 8.78.

3.2.2. Method 2 (Compounds **4d–e**)

The appropriate oxindole **1** (10 mmol) was dissolved in ethanol (100 mL) and treated with the aldehyde **2** (5 mmol) and 37% hydrochloric acid (1 mL). The reaction mixture was refluxed for 2–4 h (according to a TLC test) and cooled. The yellow to orange precipitates thus formed were collected by filtration. The crude products were purified by crystallization with ethanol (**4d**) or were treated with diethyl ether (**4e**) to give the desired products.

3,3'-((5-(tert-butyl)-2-hydroxy-1,3-phenylene)bis(methanelylidene))bis(5-chloro-1-methylindolin-2-one), **4d**, Yield 25%; IR (Nujol) ν_{\max} : 1706, 1603, 1268, 1108 cm^{-1} ; 1H -NMR (DMSO- d_6): δ 3.21 (6H, s, CH_3), 7.11 (2H, d, ind-7, $J = 8.0$), 7.31 (2H, d, ind-4, $J = 2.0$), 7.38 (2H, dd, ind-6, $J = 8.0$, $J = 2.0$), 7.75 (1H, t, ar, $J = 8.4$), 7.83 (2H, d, ar, $J = 8.4$), 7.85 (2H, s, CH), 7.92 (1H, s, ar); ^{13}C -NMR (DMSO- d_6): δ 26.11, 30.92, 34.33, 110.34, 121.69, 122.03, 122.77, 125.52, 125.85, 129.19, 129.28, 134.69, 142.72, 166.81; HRMS: m/z calculated for $C_{30}H_{27}Cl_2N_2O_3$ $[M + H]^+$: 533.13987. Found: 533.13988; Anal. Calcd for $C_{30}H_{26}Cl_2N_2O_3$ (MW: 533,45): C, 67.55; H, 4.91; N, 5.25; Found C, 67.56; H, 4.93; N, 5.22

3,3'-((5-(tert-butyl)-2-hydroxy-1,3-phenylene)bis(methanelylidene))bis(6-hydroxyindolin-2-one), **4e**, Yield 15%; IR (Nujol) ν_{\max} : 1693, 1614, 1259, 1198 cm^{-1} ; 1H -NMR (DMSO- d_6): δ 1.31 (9H, s, $3 \times CH_3$), 6.66 (4H, m, ind-4 + ind-6), 7.00 (2H, s, ar), 7.69 (2H, s, ind-7), 7.74 (2H, s, CH), 8.91 (2H, s, OH), 9.82 (1H, s, OH), 10.27 (2H, s, NH); HRMS: m/z calculated for $C_{28}H_{24}N_2NaO_5$ $[M + Na]^+$: 491.15829. Found: 491.15760; Anal. Calcd for $C_{28}H_{24}N_2O_5$ (MW: 468,51): C, 71.78; H, 5.16; N, 5.98; Found C, 71.76; H, 5.17; N, 5.99.

3.2.3. Method 3 (Compound **5b**)

The 5-bromoindolin-2-one **1b** (10 mmol) was dissolved in acetic acid (50 mL) and treated with isophthalaldehyde **3** (5 mmol) and 37% hydrochloric acid (1 mL). The reaction mixture was refluxed for 4 h and the solid separated on cooling was collected by filtration. The crude product was purified by crystallization with ethanol.

3,3'-(1,3-phenylenebis(methanelylidene))bis(5-bromoindolin-2-one), **5b**, Yield 10%; IR (Nujol) ν_{\max} : 1712, 1611, 1306, 810 cm^{-1} ; 1H -NMR (DMSO- d_6): δ 6.81 (2H, d, ind-7, $J = 8.4$), 7.36 (2H, dd, ind-6, $J = 8.4$, $J = 1.9$), 7.39 (2H, d, ind-4, $J = 1.9$), 7.70 (3H, m, 1ar + CH), 7.78 (2H, d, ar, $J = 6.8$), 7.88 (1H, s, ar), 10.76 (2H, s, NH); HRMS: m/z calculated for $C_{24}H_{15}Br_2N_2O_2$ $[M + H]^+$: 520.95003. Found: 522.94752; Anal. Calcd for $C_{24}H_{14}Br_2N_2O_2$ (MW: 522,20): C, 55.20; H, 2.70; N, 5.36; Found C, 55.18; H, 2.71; N, 5.35.

3.2.4. Method 4 (Compounds **5c–d**)

Isophthalaldehyde **3** (5 mmol) was dissolved in toluene (75 mL) and treated with the appropriate oxindole **1** (10 mmol) in the presence of 4-toluenesulfonic acid (0.5 mmol). The reaction mixture was refluxed for 1 h, and after cooling, the precipitate formed was collected by filtration. The crude derivatives were crystallized from ethanol (**5c**) or toluene (**5d**).

3,3'-(1,3-phenylenebis(methanelylidene))bis(5-chloroindolin-2-one), **5c**, Yield 30%; IR (Nujol) ν_{\max} : 1735, 1713, 1690, 800 cm^{-1} ; 1H -NMR (DMSO- d_6): δ 6.85 (2H, d, ind-7, $J = 8$), 7.23 (2H, m, ind-4), 7.25 (2H, m, ind-6), 7.71 (1H, m, ar), 7.73 (2H, s, CH), 7.79 (2H, d, ar, $J = 8$), 7.88 (1H, s, ar), 10.75 (2H, s, NH); HRMS: m/z calculated for $C_{24}H_{14}Cl_2N_2NaO_2$ $[M + Na]^+$:

455.03300. Found: 455.03226; Anal. Calcd for C₂₄H₁₄Cl₂N₂O₂ (MW: 433,29): C, 66.53; H, 3.26; N, 6.47; Found C, 66.55; H, 3.27; N, 6.43.

3,3'-(1,3-phenylenebis(methaneylylidene))bis(5-chloro-1-methylindolin-2-one), **5d**, Yield 60%; IR (Nujol) ν_{\max} : 1725, 1607, 1109, 796 cm⁻¹; ¹H-NMR (DMSO-d₆): δ 3.21 (6H, s, CH₃), 7.09(2H, d, ind-7, J = 8.0), 7.31 (2H, d, ind-4, J = 2.0), 7.38 (2H, dd, ind-6, J = 8.0, J = 2.0), 7.75 (1H, t, ar, J = 8.4), 7.83 (2H, d, ar, J = 8.4), 7.85 (2H, s, CH), 7.92 (1H, s, ar); HRMS: *m/z* calculated for C₂₆H₁₉Cl₂N₂O₂ [M + H]⁺: 461.08236. Found: 461.08213; Anal. Calcd for C₂₆H₁₈Cl₂N₂O₂ (MW: 461,34): C, 67.69; H, 3.93; N, 6.07; Found C, 67.67; H, 3.95; N, 6.08.

3.3. NCI Screening

To test the cytostatic and cytotoxic impact of the synthetic compounds, the NCI-60 Human Tumor Cell Lines Screening has been used. Leukemia, Melanoma, NSCLC, Colon, CNS, Ovarian, Renal, and Breast cancer cells (https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm, accessed on 15 August 2021) were seeded in a 96 multi-well plate at a cell density of 5000–40,000 cells/well, depending on the cell line, as described [30]. Compounds subjected to the full 5-concentration assay (**4a**, **4b**, **4c**, **4d**, **4f**, **4g**, **5b**, **5c**, **5d**, **5e**, **5f**, **8h**) and vincristine sulfate were diluted in fresh media and added to the cells at scalar concentration 0–1000 μ M or 0–100 μ M. Briefly, endpoint determinations of the cell viability or cell growth were performed at 48 h of treatment by in situ fixation of cells, which was followed by staining with a protein-binding dye, sulforhodamine B (SRB) (https://dtp.cancer.gov/discovery_development/nci-60/methodology.htm accessed on 15 August 2021). After washing, SRB optical density was measured spectrophotometrically. TGI, LC₅₀, and GI₅₀ were established according to the NCI screening procedures (https://dtp.cancer.gov/discovery_development/nci-60/methodology.htm accessed on 15 August 2021).

3.4. Cell Culture

Jurkat cells were purchased from ATCC and cultured in RPMI 1640 supplemented with 10% heat-inactivated fetal calf serum, 1% antibiotics (penicillin 5000 IU/streptomycin 5 mg/mL), and 1% L-glutamine solution (all purchased from Biochrome, Cambridge, UK). Cultured cells were maintained in 5% CO₂ and humidified air at 37 °C.

3.5. Analysis of Cell Cycle

After treatment with **5b** for 24 h, which represents the doubling time of Jurkat cells, Jurkat were fixed with 70% ice-cold ethanol and, after washing, suspended in 200 μ L of Guava cell cycle reagent (Merck Millipore, Burlington, MA, USA), containing propidium iodide. At the end of incubation at room temperature for 30 min in the dark, samples were analyzed via flow cytometry.

3.6. Analysis of Cell Viability

Jurkat cells were treated with increasing concentrations of **5b** for 24 h and analyzed with the Guava ViaCount Reagent (Merck Millipore, Burlington, MA, USA), following the manufacturer's instructions. Briefly, cells were diluted with the reagent containing 7-AAD and incubated at room temperature in the dark for 5 min before been recorded at the flow cytometer. The IC₅₀ (the half-maximal inhibitory concentration) was calculated by interpolation from the nonlinear dose–response curve.

Cell death analysis with or without specific inhibitors on Jurkat cells was performed as follows. Briefly, cells were pretreated for 1 h with or without the pan-caspase inhibitor carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone (zVAD-fmk, 10 μ M, Bachem, Bubendorf, Switzerland), the RIPK1 inhibitor necrostatin-1 s (Nec1s, 10 μ M, Abcam), the iron chelator deferoxamine (DFO, 10 μ M, Sigma-Aldrich, St. Louis, MO, USA) to respectively block apoptosis, necroptosis, or ferroptosis. Then, Jurkat cells were treated for 24 h with compound **5b**, and cell death was analyzed through the fluorescent apoptosis/necrosis (FAN) assay [31] using the cell-impermeant fluorescent nuclear probe

Sytox Green (Thermo Fisher Scientific, Waltham, MA, USA). Fluorescence was measured on a Tecan infinite 200 microplate reader.

3.7. Annexin V assay

After 1, 3, 6, or 24 h treatments with **5b**, aliquots of 2×10^4 Jurkat were resuspended in 100 μ L of RPMI 1640 containing at least 10% of FBS and stained with an equal volume of Guava Nexin Reagent (Merck KGaA, Darmstadt, Germany) containing annexin V-phycoerythrin and 7-amino-actinomycin D (7-AAD) and analyzed via flow cytometry.

3.8. Detection of Intracellular ROS

1, 3, or 6 h after **5b** treatment, cells were incubated with 2',7'-dichlorodihydro-fluorescein diacetate (H2DCFDA, 1 μ M) (Sigma-Aldrich, St. Louis, MO, USA) for 20 min at 37 °C, 5% CO₂ in the dark. Cells were washed twice and analyzed via flow cytometry.

3.9. DNA Damage Analysis

Phosphorylation of histone γ H2Ax was used as a marker of **5b** genotoxic potential. After 6 h of treatment with **5b**, cells were fixed, permeabilized, and incubated for 30 min in the dark at room temperature with an anti- γ -H2AX (Ser139) antibody clone JBW301, FITC conjugate (Merck Millipore 16-202A, Burlington, MA, USA). Etoposide 10 μ M was used as a positive control. Samples were analyzed via flow cytometry.

3.10. Flow Cytometry

EasyCyte 5HT (Merck Millipore, Burlington, MA, USA) was used to perform all flow cytometric analyses. For each sample, at least 10,000 events were recorded.

3.11. Statistical Analysis

All results are expressed as mean \pm SEM of at least three independent experiments. Differences between treatments were assessed by t-test, one-way ANOVA, or two-way ANOVA, followed by Dunnett's post-test. All statistical analyses were performed using GraphPad InStat 6.0 version (GraphPad Prism, San Diego, CA, USA). $p < 0.05$ was considered significant.

4. Conclusions

This study reports the design, synthesis, and in vitro antitumor evaluation of a panel of new bis-indolinone derivatives. After the primary screening, compound **5b** proved to be the most potent of the series and was chosen to investigate its antileukemic potential. In addition, **5b** was shown to induce a mixed type of cell death, which was apparently only partially regulated. Further studies will be needed to confirm that **5b** causes a mix of apoptosis and direct late stages of this regulated cell-death type and to directly correlate the increased ROS levels with DNA damage and cell death. Altogether, the data obtained in the study depict a promising antileukemic profile of **5b** and corroborate the rationale of the synthesis of this library of compounds. In addition, since the chemical structure seems suitable, in the future, it could be interesting to apply photodynamic therapy on **5b**, using it as a photosensitizer, trusting for an increase in potency.

Supplementary Materials: The following are available online, ¹H NMR and ¹³C NMR spectra; HRMS spectra.

Author Contributions: A.L. (Alessandra Locatelli) and C.F. conceived and designed the molecules and the experiments; A.L. (Alessandra Locatelli), A.L. (Alberto Leoni), and R.M. performed the synthesis, the purification, and the structural characterization of the synthesized compounds; E.C., C.C., V.P., performed the antiproliferative and cell death studies and data analysis; A.L. (Alessandra Locatelli), R.M. and C.F. wrote the manuscript; E.C., C.C., V.P. and A.L. (Alberto Leoni) revised the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the University of Bologna (RFO funds).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available in this article.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of the compounds are available from the corresponding author.

References

1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* **2018**, *68*, 394–424. [\[CrossRef\]](#)
2. Tang, D.; Kang, R.; Berghe, T.V.; Vandenberghe, P.; Kroemer, G. The molecular machinery of regulated cell death. *Cell Res.* **2019**, *29*, 347–364. [\[CrossRef\]](#)
3. Yang, H.; Ma, Y.; Chen, G.; Zhou, H.; Yamazaki, T.; Klein, C.; Pietrocola, F.; Vacchelli, E.; Souquere, S.; Sauvat, A.; et al. Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. *Oncoimmunology* **2016**, *5*, e1149673. [\[CrossRef\]](#) [\[PubMed\]](#)
4. Galluzzi, L.; Vitale, I.; Warren, S.; Adjemian, S.; Agostinis, P.; Martinez, A.B.; Chan, T.A.; Coukos, G.; Demaria, S.; Deutsch, E.; et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. *J. Immunother. Cancer* **2020**, *8*, e000337. [\[CrossRef\]](#)
5. Gong, Y.; Fan, Z.; Luo, G.; Yang, C.; Huang, Q.; Fan, K.; Cheng, H.; Jin, K.; Ni, Q.; Yu, X.; et al. The role of necroptosis in cancer biology and therapy. *Mol. Cancer* **2019**, *18*, 100. [\[CrossRef\]](#) [\[PubMed\]](#)
6. Dixon, S.J.; Lemberg, K.M.; Lamprecht, M.R.; Skouta, R.; Zaitsev, E.M.; Gleason, C.E.; Patel, D.N.; Bauer, A.J.; Cantley, A.M.; Yang, W.S.; et al. Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death. *Cell* **2012**, *149*, 1060–1072. [\[CrossRef\]](#) [\[PubMed\]](#)
7. Liang, C.; Zhang, X.; Yang, M.; Dong, X. Recent Progress in Ferroptosis Inducers for Cancer Therapy. *Adv. Mater.* **2019**, *31*, e1904197. [\[CrossRef\]](#) [\[PubMed\]](#)
8. Leoni, A.; Locatelli, A.; Morigi, R.; Rambaldi, M. 2-Indolinone a versatile scaffold for treatment of cancer: A patent review (2008–2014). *Expert Opin. Ther. Pat.* **2015**, *26*, 149–173. [\[CrossRef\]](#)
9. Andreani, A.; Bellini, S.; Burnelli, S.; Granaiola, M.; Leoni, A.; Locatelli, A.; Morigi, R.; Rambaldi, M.; Varoli, L.; Calonghi, N.; et al. Substituted E-3-(3-Indolylmethylene)-1,3-dihydroindol-2-ones with Antitumor Activity. In-depth Study of the Effect on Growth of Breast Cancer Cells. *J. Med. Chem.* **2010**, *53*, 5567–5575. [\[CrossRef\]](#)
10. Andreani, A.; Granaiola, M.; Locatelli, A.; Morigi, R.; Rambaldi, M.; Varoli, L.; Calonghi, N.; Cappadone, C.; Farruggia, G.; Stefanelli, C.; et al. Substituted 3-(5-Imidazo[2,1-b]thiazolylmethylene)-2-indolinones and Analogues: Synthesis, Cytotoxic Activity, and Study of the Mechanism of Action. *J. Med. Chem.* **2012**, *55*, 2078–2088. [\[CrossRef\]](#)
11. Leoni, A.; Locatelli, A.; Morigi, R.; Rambaldi, M.; Cappadone, C.; Farruggia, G.; Iotti, S.; Merolle, L.; Zini, M.; Stefanelli, C. New substituted E-3-(3-indolylmethylene)1,3-dihydroindol-2-ones with antiproliferative activity. Study of effects on HL-60 leukemia cells. *Eur. J. Med. Chem.* **2014**, *79*, 298–339. [\[CrossRef\]](#)
12. Morigi, R.; Locatelli, A.; Leoni, A.; Rambaldi, M.; Bortolozzi, R.; Mattiuzzo, E.; Ronca, R.; Maccarinelli, F.; Hamel, E.; Bai, R.; et al. Synthesis, in vitro and in vivo biological evaluation of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones as new potent anticancer agents. *Eur. J. Med. Chem.* **2019**, *166*, 514–530. [\[CrossRef\]](#)
13. Andreani, A.; Burnelli, S.; Granaiola, M.; Leoni, A.; Locatelli, A.; Morigi, R.; Rambaldi, M.; Varoli, L.; Landi, L.; Prata, C.; et al. Antitumor Activity of Bis-indole Derivatives. *J. Med. Chem.* **2008**, *51*, 4563–4570. [\[CrossRef\]](#) [\[PubMed\]](#)
14. Andreani, A.; Burnelli, S.; Granaiola, M.; Leoni, A.; Locatelli, A.; Morigi, R.; Rambaldi, M.; Varoli, L.; Landi, L.; Prata, C.; et al. Antitumor activity and COMPARE analysis of bis-indole derivatives. *Bioorg. Med. Chem.* **2010**, *18*, 3004–3011. [\[CrossRef\]](#) [\[PubMed\]](#)
15. Efimova, I.; Catanzaro, E.; Van Der Meeren, L.; Turbanova, V.D.; Hammad, H.; Mishchenko, T.A.; Vedunova, M.V.; Fimognari, C.; Bachert, C.; Coppieters, F.; et al. Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity. *J. Immunother. Cancer* **2020**, *8*, e001369. [\[CrossRef\]](#) [\[PubMed\]](#)
16. Shlomovitz, I.; Speir, M.; Gerlic, M. Flipping the dogma—Phosphatidylserine in non-apoptotic cell death. *Cell Commun. Signal.* **2019**, *17*, 139. [\[CrossRef\]](#) [\[PubMed\]](#)
17. Šalipur, F.R.; Reyes-Reyes, E.M.; Xu, B.; Hammond, G.B.; Bates, P.J. A novel small molecule that induces oxidative stress and selectively kills malignant cells. *Free Radic. Biol. Med.* **2014**, *68*, 110–121. [\[CrossRef\]](#) [\[PubMed\]](#)
18. Digby, E.M.; Rana, R.; Nitz, M.; Beharry, A.A. DNA directed damage using a brominated DAPI derivative. *Chem. Commun.* **2019**, *55*, 9971–9974. [\[CrossRef\]](#)
19. Demchenko, A.P. Beyond annexin V: Fluorescence response of cellular membranes to apoptosis. *Cytotechnology* **2013**, *65*, 157–172. [\[CrossRef\]](#)
20. Roos, W.P.; Kaina, B. DNA damage-induced cell death by apoptosis. *Trends Mol. Med.* **2006**, *12*, 440–450. [\[CrossRef\]](#)
21. Donohoe, C.; Senge, M.O.; Arnaut, L.G.; da Silva, L.C. Cell death in photodynamic therapy: From oxidative stress to anti-tumor immunity. *BBA Rev. Cancer* **2019**, *1872*, 188308. [\[CrossRef\]](#)

22. Sun, L.; Tran, N.; Tang, F.; App, H.; Hirth, P.; McMahon, G.; Tang, C. Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases. *J. Med. Chem.* **1998**, *41*, 2588–2603. [[CrossRef](#)]
23. Huisgen, R.; König, H.; Lepley, A.R. Nucleophile aromatische Substitutionen, XVIII. Neue Ringschlüsse über Arine. *Chem. Ber.* **1960**, *93*, 1496–1506. [[CrossRef](#)]
24. Beer, R.J.S.; Davenport, H.F.; Robertson, A. Some extensions of the synthesis of hydroxyindoles from *p*-benzoquinones. *J. Chem. Soc.* **1953**, 1262–1264. [[CrossRef](#)]
25. Porter, J.C.; Robinson, R.; Wyler, M. Monothiophthalimide and some derivatives of oxindole. *J. Chem. Soc.* **1941**, 620–624. [[CrossRef](#)]
26. Mayer, F.; Oppenheimer, T. Über Naphthyl-essigsäuren. 3. Abhandlung: 1-Nitronaphthyl-2-brenztraubensäure und 1-Nitronaphthyl-2-essigsäure. *Chem. Ber.* **1918**, *51*, 1239–1245. [[CrossRef](#)]
27. Andreani, A.; Rambaldi, M.; Locatelli, A.; Bossa, R.; Galatulas, I.; Ninci, M. Synthesis and cardiotoxic activity of 2-indolinones. *Eur. J. Med. Chem.* **1990**, *25*, 187–190. [[CrossRef](#)]
28. Andreani, A.; Granaiola, M.; Leoni, A.; Locatelli, A.; Morigi, R.; Rambaldi, M.; Garaliene, V. Synthesis and Antitumor Activity of 1,5,6-Substituted *E*-3-(2-Chloro-3-indolylmethylene)-1,3-dihydroindol-2-ones. *J. Med. Chem.* **2002**, *45*, 2666–2669. [[CrossRef](#)] [[PubMed](#)]
29. Amato, J.; Morigi, R.; Pagano, B.; Pagano, A.; Ohnmacht, S.; De Magis, A.; Tiang, Y.-P.; Capranico, G.; Locatelli, A.; Graziadio, A.; et al. Toward the Development of Specific G-Quadruplex Binders: Synthesis, Biophysical, and Biological Studies of New Hydrazone Derivatives. *J. Med. Chem.* **2016**, *59*, 5706–5720. [[CrossRef](#)]
30. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; et al. Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines. *J. Natl. Cancer Inst.* **1991**, *83*, 757–766. [[CrossRef](#)] [[PubMed](#)]
31. Grootjans, S.; Hassannia, B.; Delrue, I.; Goossens, V.; Wiernicki, B.; Dondelinger, Y.; Bertrand, M.; Krysko, D.; Vuylsteke, M.; Vandenabeele, P.; et al. A real-time fluorometric method for the simultaneous detection of cell death type and rate. *Nat. Protoc.* **2016**, *11*, 1444–1454. [[CrossRef](#)] [[PubMed](#)]